Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke: a nested case-control...

Area of Science:

• Cardiovascular Research
• Immunology
• Epidemiology

Background:

• Autoantibodies against oxidized low-density lipoprotein (LDL) are implicated in atherosclerosis.
• Previous research on their role in stroke pathogenesis is inconsistent.
• This study aimed to clarify the association between these autoantibodies and future stroke risk.

Purpose of the Study:

• To investigate the association between autoantibodies against oxidatively modified LDL and the incidence of future stroke.
• To determine if specific antibody types (IgG, IgA, IgM) against copper-oxidized LDL and malonaldehyde (MDA)-LDL are predictive of stroke.
• To analyze these associations in a large, prospective cohort.

Main Methods:

• A prospective case-control study involving 44,725 participants from the MONICA and VIP projects.
• Follow-up period from January 1, 1985, to August 31, 1996.
• Analysis of antibodies against copper-oxidized LDL and MDA-LDL using ELISA, comparing 119 stroke cases with 233 matched controls.

Main Results:

• No significant differences in IgG, IgA, or IgM autoantibody levels against copper-oxidized LDL or MDA-LDL were found between stroke cases and controls.
• Adjusted risk ratios indicated that these autoantibodies do not confer a stroke risk.
• Stroke patients exhibited higher levels of triglycerides, fasting blood sugar, blood pressure, and a greater prevalence of hypertension and diabetes mellitus.

Conclusions:

• Autoantibodies against oxidatively modified LDL are not identified as a risk factor for stroke in the studied adult population.
• Traditional risk factors like hypertension, diabetes, and elevated triglycerides remain significant predictors of stroke.
• Further research may be needed to explore other immunological markers in stroke etiology.